{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Cancer&page=32", "query": { "condition": "Neuroendocrine Cancer", "page": 32 }, "page_size": 10 }, "pagination": { "page": 32, "page_size": 10, "total_count": 2742, "total_pages": 275, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Cancer&page=33&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Cancer&page=31&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T10:57:35.196Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02196181", "title": "Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage III Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Unresectable Melanoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dabrafenib Mesylate", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Trametinib Dimethyl Sulfoxide", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 280, "start_date": "2014-09-19", "completion_date": "2027-03-15", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-24T10:57:35.196Z", "location_count": 752, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 464 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02196181" }, { "nct_id": "NCT00358319", "title": "Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "Karenitecin", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2005-03", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2013-11-25", "last_synced_at": "2026-10-24T10:57:35.196Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00358319" }, { "nct_id": "NCT06237881", "title": "A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Melanoma", "Lung Neoplasms", "Head and Neck Neoplasms" ], "interventions": [ { "name": "KSQ-001EX", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2024-01-31", "completion_date": "2029-01-01", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-24T10:57:35.196Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06237881" }, { "nct_id": "NCT01586195", "title": "Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "Vemurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 31, "start_date": "2011-10-31", "completion_date": "2015-04-30", "has_results": true, "last_update_posted_date": "2017-05-25", "last_synced_at": "2026-10-24T10:57:35.196Z", "location_count": 15, "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01586195" }, { "nct_id": "NCT00442533", "title": "Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "Indium-111 pentetreotide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Radio Isotope Therapy of America", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2005-08", "completion_date": "2015-12-28", "has_results": false, "last_update_posted_date": "2023-04-03", "last_synced_at": "2026-10-24T10:57:35.196Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00442533" }, { "nct_id": "NCT00368615", "title": "Characterization of the Melanoma-Specific Immune Response", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Melanoma" ], "interventions": [], "intervention_types": [], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 20, "start_date": "2007-08", "completion_date": "2024-08", "has_results": false, "last_update_posted_date": "2024-01-23", "last_synced_at": "2026-10-24T10:57:35.196Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00368615" }, { "nct_id": "NCT02978625", "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Large Cell Lymphoma, ALK-Negative", "Anaplastic Large Cell Lymphoma, ALK-Positive", "Apocrine Carcinoma", "Carcinoma Arising From Cylindroma", "Carcinoma Arising From Spiradenoma", "Digital Papillary Adenocarcinoma", "Endocrine Mucin-Producing Sweat Gland Carcinoma", "Extramammary Paget Disease", "Extraocular Sebaceous Carcinoma", "Hidradenocarcinoma", "Malignant Sweat Gland Neoplasm", "Merkel Cell Carcinoma", "Microcystic Adnexal Carcinoma", "NK-Cell Lymphoma, Unclassifiable", "Papillary Adenocarcinoma", "Porocarcinoma", "Primary Cutaneous Mucinous Carcinoma", "Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Recurrent T-Cell Non-Hodgkin Lymphoma", "Refractory Anaplastic Large Cell Lymphoma", "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Refractory Merkel Cell Carcinoma", "Refractory Mycosis Fungoides", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Refractory Skin Squamous Cell Carcinoma", "Refractory T-Cell Non-Hodgkin Lymphoma", "Sezary Syndrome", "Signet Ring Cell Adenocarcinoma", "Skin Adenoid Cystic Carcinoma", "Skin Adnexal Carcinoma", "Skin Basal Cell Carcinoma", "Skin Basosquamous Cell Carcinoma", "Skin Keratoacanthoma", "Skin Squamous Cell Carcinoma", "Squamoid Eccrine Ductal Carcinoma", "Squamous Cell Carcinoma of Unknown Primary", "Sweat Gland Carcinoma", "Trichilemmal Carcinoma", "Vulvar Squamous Cell Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Mammography", "type": "PROCEDURE" }, { "name": "Talimogene Laherparepvec", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2017-09-27", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-24T10:57:35.196Z", "location_count": 36, "location_summary": "Los Angeles, California • Orange, California • Pasadena, California + 28 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02978625" }, { "nct_id": "NCT04066725", "title": "Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "Aspirin 81 mg", "type": "DRUG" }, { "name": "Aspirin 325mg", "type": "DRUG" }, { "name": "Placebo oral tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2019-07-25", "completion_date": "2021-03-19", "has_results": false, "last_update_posted_date": "2022-02-18", "last_synced_at": "2026-10-24T10:57:35.196Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04066725" }, { "nct_id": "NCT02348749", "title": "18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "18F-MFBG (meta-fluoro benzylguanidine)", "type": "RADIATION" }, { "name": "Positron emission tomography (PET) imaging", "type": "DEVICE" }, { "name": "Blood draws", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "DEVICE", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": null, "sex": "ALL", "summary": "5 Years and older" }, "enrollment_count": 48, "start_date": "2015-01", "completion_date": "2025-03-17", "has_results": false, "last_update_posted_date": "2025-03-19", "last_synced_at": "2026-10-24T10:57:35.196Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02348749" }, { "nct_id": "NCT02652455", "title": "Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Melanoma (Skin)", "Skin Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Surgery to Remove Tumor for Growth of TIL", "type": "PROCEDURE" }, { "name": "CD137", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "TIL Infusion", "type": "BIOLOGICAL" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2016-03-08", "completion_date": "2020-08-30", "has_results": false, "last_update_posted_date": "2025-08-19", "last_synced_at": "2026-10-24T10:57:35.196Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02652455" } ] }